Multiple preclinical studies have provided evidence that stimulation of GITR (TNFRSF18) in the tumor microenvironment contributes to costimulatory activation of CD4 and CD8 T-cells, while inhibiting/depleting intra-tumoral regulatory T cells [33]. The gene discussed is CD4; the disease is neoplasm.